Carcinoid syndrome natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to a 20% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years. | Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to a 20% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years. | ||
==Natural History , Complications and Prognosis== | |||
===Complications=== | |||
* Increased risk of falls and injury (from [[hypotension]]) | |||
* Bowel [[obstruction]] (from tumor) | |||
* [[Gastrointestinal bleeding]] | |||
* Right-sided [[heart failure]] | |||
===Prognosis=== | |||
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome. | |||
In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time. | |||
The outlook is more favorable with new treatment methods, such as [[Sandostatin]]. | |||
==References== | ==References== | ||
Revision as of 17:13, 10 September 2012
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome natural history, complications and prognosis |
|
FDA on Carcinoid syndrome natural history, complications and prognosis |
|
CDC on Carcinoid syndrome natural history, complications and prognosis |
|
Carcinoid syndrome natural history, complications and prognosis in the news |
|
Blogs on Carcinoid syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to a 20% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years.
Natural History , Complications and Prognosis
Complications
- Increased risk of falls and injury (from hypotension)
- Bowel obstruction (from tumor)
- Gastrointestinal bleeding
- Right-sided heart failure
Prognosis
The outlook in patients with carcinoid syndrome is different from the outlook in patients who have carcinoid tumors without the syndrome. In people with the syndrome, the tumor has usually spread to the liver, which lowers the survival rate. People with carcinoid syndrome are also more likely to have a separate cancer (second primary tumor) at the same time. The outlook is more favorable with new treatment methods, such as Sandostatin.